Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHANDRAKANT MEHTA

NPI
1326093402
CMS profile
14216
Location
HEMET, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,142.70

115 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,142.70 115

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHANDRAKANT MEHTA

NPI 1326093402 · CMS profile ID 14216

HEMET, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326093402?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHANDRAKANT MEHTA, NPI 1326093402, CMS profile ID 14216. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326093402?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CHANDRAKANT MEHTA, NPI 1326093402, CMS profile ID 14216. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326093402?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CHANDRAKANT MEHTA, NPI 1326093402, CMS profile ID 14216, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–115 of 115 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1326093402?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

115 matching records · $2,142.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 115 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–115 of 115.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $20.4501/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200720892 CMS
ABBVIE INC. $31.3001/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203066086 CMS
Amgen Inc. $13.1001/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227114247 CMS
AstraZeneca Pharmaceuticals LP $21.3201/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214785456 CMS
ABBVIE INC. $0.3401/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203066082 CMS
ABBVIE INC. $8.7001/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203066084 CMS
Janssen Biotech, Inc. $6.9001/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174629405 CMS
ABBVIE INC. $5.4101/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203066080 CMS
ABBVIE INC. $13.5401/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203066078 CMS
Janssen Biotech, Inc. $3.6001/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174629246 CMS
PFIZER INC. $22.2301/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228855625 CMS
UCB, Inc. $40.3001/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224422364 CMS
ABBVIE INC. $11.3601/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203066076 CMS
Alexion Pharmaceuticals, Inc. $20.4701/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211399126 CMS
Janssen Biotech, Inc. $4.5901/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174629456 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,176.69 129
PY2020 $383.31 25
PY2021 $728.77 34
PY2022 $1,495.17 72
PY2023 $1,939.75 87
PY2024 $1,793.90 81
PY2025 $2,142.70 115

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,252,951.86 10
PY2024 Recipient $104.58 1
PY2024 Principal investigator $1,697,281.62 3
PY2023 Principal investigator $16,647.97 4
PY2022 Recipient $51.00 1
PY2022 Principal investigator $91,260.52 19
PY2021 Recipient $361.00 1
PY2021 Principal investigator $103,423.77 20
PY2020 Recipient $96.70 1
PY2020 Principal investigator $104,131.33 34
PY2019 Recipient $768.84 1
PY2019 Principal investigator $69,473.16 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $43,525.80 12/01/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225336275
Principal investigator 2 American Regent $130,535.20 09/03/2025 Non-covered Recipient Entity
Biovin Enterprise LLC
TPX-100 No dispute reported 06/30/2026 1232689987
Principal investigator 1 Eli Lilly and Company $31,861.00 05/27/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187876177
Principal investigator 1 Amgen Inc. $393,228.00 05/05/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246644355
Principal investigator 1 Amgen Inc. $195,089.58 04/28/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639725
Principal investigator 1 Eli Lilly and Company $2,079.86 02/25/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187880823
Principal investigator 1 Eli Lilly and Company $85,448.00 02/11/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187876125
Principal investigator 1 ABBVIE INC. $6,132.65 01/13/2025 Non-covered Recipient Entity
C V MEHTA MD MEDICAL CORPORATION
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202438127
Principal investigator 1 Amgen Inc. $2,287,472.32 01/10/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH - CACTUS AVENUE
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246644340
Principal investigator 1 AstraZeneca UK Limited $77,579.45 01/08/2025 Non-covered Recipient Entity
C V MEHTA MD MEDICAL CORP
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus No dispute reported 06/30/2026 1185537960